• Trill Impact Ventures led a USD 6 million Series A extension round in Zafrens alongside existing investor imec.xpand.
• San Diego-based Zafrens develops an ultra-high-throughput experimental platform to test biological hypotheses for drug discovery.
• The financing will support Zafrens’ internal drug pipeline and expansion of its proprietary Z-Screen platform.
• The deal marks the investor’s first investment in TechBio, which combines biology, technology and data.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trill Impact AB published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.